"Infliximab Safety Letters"

Study safety letters, correspondence with the Riverside Research Ethics Committee (RREC), adverse event reporting, Schering Plough correspondence, reporting of suspect adverse reaction reports to Remicade/infliximab in varied studies, pharmaceutical company drug safety letters, Centocor investigator letters, Janssen/Centocor case summaries, pharmaceutical safety surveillance and ethics committee approval.

2001-2004

1 file (in 4 parts)

This item requires facilitated access. Email library@wellcomecollection.org to request an appointment. This item is also restricted. You will need to complete a Restricted Access form agreeing to anonymise personal data before you will be allowed to view this item. Please see our Access Policy for more details. Restricted until 1 January 2089.